- Home
- UFCS vs BBOT Comparison
UFCS vs BBOT Comparison
Compare UFCS & BBOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UFCS
- BBOT
- Stock Information
- Founded
- UFCS 1946
- BBOT 2016
- Country
- UFCS United States
- BBOT United States
- Employees
- UFCS N/A
- BBOT N/A
- Industry
- UFCS Property-Casualty Insurers
- BBOT Biotechnology: Pharmaceutical Preparations
- Sector
- UFCS Finance
- BBOT Health Care
- Exchange
- UFCS Nasdaq
- BBOT Nasdaq
- Market Cap
- UFCS 765.5M
- BBOT 822.9M
- IPO Year
- UFCS N/A
- BBOT N/A
- Fundamental
- Price
- UFCS $30.93
- BBOT $12.41
- Analyst Decision
- UFCS Buy
- BBOT Strong Buy
- Analyst Count
- UFCS 2
- BBOT 4
- Target Price
- UFCS $30.50
- BBOT $25.00
- AVG Volume (30 Days)
- UFCS 120.7K
- BBOT 362.3K
- Earning Date
- UFCS 11-04-2025
- BBOT 11-26-2025
- Dividend Yield
- UFCS 2.05%
- BBOT N/A
- EPS Growth
- UFCS 143.32
- BBOT N/A
- EPS
- UFCS 3.51
- BBOT N/A
- Revenue
- UFCS $1,322,727,000.00
- BBOT N/A
- Revenue This Year
- UFCS $12.34
- BBOT N/A
- Revenue Next Year
- UFCS $14.56
- BBOT N/A
- P/E Ratio
- UFCS $8.92
- BBOT N/A
- Revenue Growth
- UFCS 14.18
- BBOT N/A
- 52 Week Low
- UFCS $19.19
- BBOT $8.70
- 52 Week High
- UFCS $32.58
- BBOT $13.05
- Technical
- Relative Strength Index (RSI)
- UFCS 52.30
- BBOT N/A
- Support Level
- UFCS $29.75
- BBOT N/A
- Resistance Level
- UFCS $31.65
- BBOT N/A
- Average True Range (ATR)
- UFCS 0.68
- BBOT 0.00
- MACD
- UFCS -0.09
- BBOT 0.00
- Stochastic Oscillator
- UFCS 40.28
- BBOT 0.00
About UFCS United Fire Group Inc.
United Fire Group Inc is engaged in the business of writing property and casualty insurance and selling annuities through a network of independent agencies. The company's only operating segment is property and casualty insurance, which includes commercial lines insurance, personal lines insurance, and assumed reinsurance. The primary source of revenue is premium and investment income.
About BBOT BridgeBio Oncology Therapeutics Inc. Common Stock
BridgeBio Oncology Therapeutics Inc, formerly BridgeBio Oncology Therapeutics is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes.